Geron Corp. announced that results from IMbark, a phase II clinical trial of imetelstat treatment in Intermediate-II or High-risk myelofibrosis patients who are relapsed or refractory to a Janus Kinase inhibitor, were presented at ASH.
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
